Researchers at Albert Einstein College of Medicine of Yeshiva University report in the September 4 online edition of Nature Medicine that they have developed a tuberculosis (TB) vaccine candidate that proved both potent and safe in animal studies.
According to the World Health Organization, TB kills an estimated 1.7 million people each year and infects one out of three people around the globe. With drug-resistant strains spreading, a vaccine for preventing TB is urgently needed.
"Producing effective TB vaccines requires a better understanding of the mechanisms used by Mycobacterium tuberculosis [the bacterial species that causes TB] to evade the bodys immune responses," says senior author William Jacobs, Jr., PhD, professor of microbiology & immunology and of genetics at Einstein and a Howard Hughes Medical Institute investigator. He notes that the only currently used vaccine, the Bacille Calmette-Guérin (BCG) vaccine, has been notoriously inconsistent in protecting against TB.
To determine how M. tuberculosis outwits the immune response, Jacobs and his colleagues worked with a closely related species known as Mycobacterium smegmatis that is lethal to mice at high doses but does not harm people. The researchers created a version of M. smegmatis lacking a set of genes, known as ESX-3, considered crucial for evading host immunity. When high doses of the altered bacteria were infused into mice, it became clear that bacteria lacking the ESX-3genes could no longer evade their hosts immune system: the mice controlled and cleared the infection through a robust T-cell responsethe same response a successful TB vaccine would elicit.
Unfortunately, Jacobs found that removing the same set of genes from M. tuberculosis killed the bacteriumwhich meant M. tuberculosis could not be manipulated in this way to make a vaccine. But Dr. Jacobs and his colleagues found a way around this stumbling block. They took the M. smegmatis bacteria lacking ESX-3 and inserted the analogous set of M. tuberculosis ESX-3 genes. These M. smegmatis bacteria were then infused into mice, which once again fought off the infection. And eight weeks later, when the mice were challenged with high doses of M. tuberculosiswhich kills mice as well as peoplethese "vaccinated" mice lived much longer than control mice: an average survival time of 135 days versus 54 days.
Just as impressive, says Jacobs, was the markedly reduced level of TB bacteria found in the animals tissues. "Most notably," he said, "those vaccinated animals that survived for more than 200 days had livers that were completely clear of TB bacteria, and nobody has ever seen that before."
Jacobs cautioned that only about one in five mice showed this robust responseindicating that the vaccine must be improved before it can be considered sufficiently effective. "We dont even know yet if it will work in humans, but its certainly a significant step in efforts to create a better TB vaccine," he says.
Aeras, a Rockville, Md.-based non-profit development partnership dedicated to preventing TB, has licensed the technology described in this study and is using it to develop a new TB vaccine. The technology could also provide the basis for vaccines that eliminate leprosy and other virulent mycobacteria from infected tissues.